uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden
NU Hosp Grp, Dept Med, Trollhattan Uddevalla, Sweden.;Univ Gothenburg, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden..
Domnarvet VC, Borlange, Sweden..
Pygargus, Stockholm, Sweden..
Primary Hlth Care, Res & Dev Unit, Narhalsan, Vanersborg, Sweden..
Show others and affiliations
2016 (English)In: Diabetes Therapy, ISSN 1869-6953, E-ISSN 1869-6961, Vol. 7, no 2, 321-333 p.Article in journal (Refereed) PublishedText
Abstract [en]

Introduction: The aim of the present study was to use real-world data from Swedish primary-care and national registries to understand clinical outcomes in patients with Type 2 diabetes (T2D) treated with liraglutide in clinical practice, and to compare with data from those treated with sitagliptin. Methods: This was a non-interventional, retrospective study conducted between February 2014 and September 2014 using T2D patient data from Swedish primary-care centers and national healthcare registries. The primary objective was to assess the effectiveness of liraglutide in control of glycemia and body weight in clinical practice (stage 1). The secondary objective was to compare the clinical effectiveness of liraglutide with sitagliptin on glycemic control and body weight in clinical practice in a propensity-score-matched population (stage 2). Results: In stage 1 (n = 402), 39.4% of patients treated with liraglutide achieved >= 1.0% (10.9 mmol/mol) reduction in glycated hemoglobin (HbA1c) after 180 days of treatment and 54.9% achieved the target HbA1c of <7.0% (53.0 mmol/mol). Moreover, compared with baseline, 22.5% of patients treated with liraglutide achieved both >= 1.0% reduction in HbA1c and >= 3.0% reduction in body weight. In stage 2, a significantly greater proportion of patients receiving liraglutide (n = 180) than sitagliptin (n = 208) achieved >= 1.0% reduction in HbA1c [52.9% vs 33.5%, respectively (P = 0.0002)]. Mean body-weight loss was also significantly greater in patients receiving liraglutide vs sitagliptin [-3.5 vs -1.3 kg, respectively (P < 0.0001)]. Conclusion: This study provides real-world evidence from Sweden corroborating previous clinical trials that demonstrate greater efficacy of liraglutide over sitagliptin on glycemic control and body-weight reduction in patients with T2D.

Place, publisher, year, edition, pages
2016. Vol. 7, no 2, 321-333 p.
Keyword [en]
Liraglutide, Real-world evidence, Sitagliptin, Sweden, Type 2 diabetes
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-299583DOI: 10.1007/s13300-016-0173-zISI: 000377940300012PubMedID: 27216947OAI: oai:DiVA.org:uu-299583DiVA: diva2:949714
Novo Nordisk
Available from: 2016-07-22 Created: 2016-07-22 Last updated: 2016-07-22Bibliographically approved

Open Access in DiVA

fulltext(670 kB)43 downloads
File information
File name FULLTEXT01.pdfFile size 670 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Johansson, Gunnar
By organisation
Family Medicine and Preventive Medicine
In the same journal
Diabetes Therapy
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 43 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 85 hits
ReferencesLink to record
Permanent link

Direct link